Merck & Co/Eisai’s Clear study results look better than Bristol/Exelixis’s Checkmate-9ER, but the big loser could be Pfizer.
Full data from the Checkmate-9ER trial suggest a new combo to match Merck & Co’s Keytruda plus Inlyta in first-line renal cancer.
Though late-breakers rightfully seize much of the limelight at the Esmo congress, investors should look further afield too.
This week another takeover included a CVR element, confirming a trend that has been gaining traction over the past year.
A failed phase III trial has Ipsen clutching at straws to salvage its rare bone disease project palovarotene, which it bought for $1bn a mere 11 months ago.